Hypothesis versus association: The optimal hemoglobin target debate

Giovanni F.M. Strippoli, Jonathan C. Craig

Research output: Contribution to journalEditorial

9 Citations (Scopus)


IN THIS ISSUE of the American Journal of Kidney Diseases, Levin et al1 present the results of their Canadian randomized trial of early versus delayed anemia management with high (12.0 to 14.0 g/dL [120 to 140 g/L]) versus low (9.0 to 10.5 g/dL [90 to 105 g/L]) hemoglobin (Hb) level targets in patients with chronic kidney disease (CKD). This study is presented within a year of the publication of 2 other trials with similar designs addressing similar questions2, 3 and when preliminary results of the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study are coming into the public domain.4
Original languageEnglish
Pages (from-to)970-973
Number of pages4
JournalAmerican Journal of Kidney Diseases
Issue number5
Publication statusPublished - 2005
Externally publishedYes


  • CREATE stutdy
  • anemia management
  • bias
  • randomization
  • outcomes


Dive into the research topics of 'Hypothesis versus association: The optimal hemoglobin target debate'. Together they form a unique fingerprint.

Cite this